- Market Driver: The increasing use of off-label pharmacological treatment for CFS is driving the growth of the market. Graded exercise and CBT are considered the first-line treatment for CFS. Patients with CFS are more likely to consult a complementary or alternative healthcare provider instead of a physiotherapist or psychologist for advice and support. As there are no approved drugs for the treatment of CFS, a wide range of pain relievers, antidepressants, antibiotics, and immunomodulators are being prescribed off-label for improving symptoms.
- Market Challenge: The confirmation of specific diagnostic tests for confirmation of CFS is challenging the growth of the market. CFS can be a symptom of other medical conditions, such as chronic mononucleosis, fibromyalgia, neurological conditions, Lyme disease, and sensitivity to certain chemicals. It can also be a symptom in many treatable diseases such as depression, cancer, subacute or chronic infections, psychosomatic diseases, and malingering. Thus, more education is required about CFS among healthcare professionals. Such factors may challenge the market growth in the forecast years.
Technavio provides drivers, trends, and challenges that will impact the future of the market.
View a Sample Report
Market Segmentation
North America will be the leading region with 42% of the market's growth during the forecast period. The growth is attributed to factors such as high per capita pharmaceutical expenditure, access to advanced healthcare, the strong market presence of leading vendors, and the increasing awareness about CFS. Moreover, market growth in this region will be faster than the growth of the market in other regions. The US and Canada are the key countries for the chronic fatigue syndrome therapeutics market in North America. The growing prevalence of CFS in the US is also driving the growth of the regional market. According to the Centers for Disease Control (CDC), the prevalence of CFS in the US is around 11.5%.
The pain relievers and NSAIDs segment will have significant market share growth during the forecast period. Pain relievers are the most commonly used drugs, as they can help in relieving pain and reducing inflammation. Ibuprofen is the most commonly used NSAID. Body pain is the most frequently reported reason for the use of NSAIDs in CFS patients. Arthritis and headache are the second-most and the third-most frequently reported reasons, respectively.
Learn about the contribution of each segment summarized in concise infographics and thorough descriptions.
View a Sample Report
Some Companies Mentioned
- AIM ImmunoTech Inc.
- Apotex Inc.
- Aurobindo Pharma Ltd.
- Bionpharma Inc.
- Cadila Pharmaceuticals Ltd.
- Hikma Pharmaceuticals Plc
- Lupin Ltd.
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
Want your report customized?
Speak to an analyst
and personalize your report according to your needs.
Related Reports
Narcolepsy Drugs Market by Type and Geography - Forecast and Analysis 2022-2026
Mental Health Market by Service and Geography - Forecast and Analysis 2022-2026
Chronic Fatigue Syndrome Therapeutics Market Scope |
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 4.31% |
Market growth 2022-2026 |
USD 51.84 million |
Market structure |
Concentrated |
YoY growth (%) |
3.8 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 42% |
Key consumer countries |
US, Canada, Germany, UK, France, US, Canada, Germany, UK, and France |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
AIM ImmunoTech Inc., Apotex Inc., Aurobindo Pharma Ltd., Bionpharma Inc., Cadila Pharmaceuticals Ltd., Hikma Pharmaceuticals Plc, Lupin Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. |
Market Dynamics |
Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Browse Health Care Market Research Reports
Key Topics Covered:
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
- 4.2 Bargaining power of buyers
- Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.7 Market condition
- Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Product
- 5.1 Market segments
- Exhibit 24: Chart on Product - Market share 2021-2026 (%)
- Exhibit 25: Data Table on Product - Market share 2021-2026 (%)
- 5.2 Comparison by Product
- Exhibit 26: Chart on Comparison by Product
- Exhibit 27: Data Table on Comparison by Product
- 5.3 Pain relievers and NSAIDs - Market size and forecast 2021-2026
- Exhibit 28: Chart on Pain relievers and NSAIDs - Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Pain relievers and NSAIDs - Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Pain relievers and NSAIDs - Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Pain relievers and NSAIDs - Year-over-year growth 2021-2026 (%)
- 5.4 Antidepressant and antipsychotic drugs - Market size and forecast 2021-2026
- Exhibit 32: Chart on Antidepressant and antipsychotic drugs - Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on Antidepressant and antipsychotic drugs - Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on Antidepressant and antipsychotic drugs - Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Antidepressant and antipsychotic drugs - Year-over-year growth 2021-2026 (%)
- 5.5 Antimicrobial and immunomodulatory drugs - Market size and forecast 2021-2026
- Exhibit 36: Chart on Antimicrobial and immunomodulatory drugs - Market size and forecast 2021-2026 ($ million)
- Exhibit 37: Data Table on Antimicrobial and immunomodulatory drugs - Market size and forecast 2021-2026 ($ million)
- Exhibit 38: Chart on Antimicrobial and immunomodulatory drugs - Year-over-year growth 2021-2026 (%)
- Exhibit 39: Data Table on Antimicrobial and immunomodulatory drugs - Year-over-year growth 2021-2026 (%)
- 5.6 Market opportunity by Product
- Exhibit 40: Market opportunity by Product ($ million)
6 Customer Landscape
- 6.1 Customer landscape overview
- Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 42: Chart on Market share by geography 2021-2026 (%)
- Exhibit 43: Data Table on Market share by geography 2021-2026 (%)
- 7.2 Geographic comparison
- Exhibit 44: Chart on Geographic comparison
- Exhibit 45: Data Table on Geographic comparison
- 7.3 North America - Market size and forecast 2021-2026
- Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%)
- Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%)
- 7.4 Europe - Market size and forecast 2021-2026
- Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)
- 7.5 Asia - Market size and forecast 2021-2026
- Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)
- 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
- Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- 7.7 US - Market size and forecast 2021-2026
- Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%)
- 7.8 Germany - Market size and forecast 2021-2026
- Exhibit 66: Chart on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on Germany - Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on Germany - Year-over-year growth 2021-2026 (%)
- 7.9 UK - Market size and forecast 2021-2026
- Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%)
- 7.10 Canada - Market size and forecast 2021-2026
- Exhibit 74: Chart on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on Canada - Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on Canada - Year-over-year growth 2021-2026 (%)
- 7.11 France - Market size and forecast 2021-2026
- Exhibit 78: Chart on France - Market size and forecast 2021-2026 ($ million)
- Exhibit 79: Data Table on France - Market size and forecast 2021-2026 ($ million)
- Exhibit 80: Chart on France - Year-over-year growth 2021-2026 (%)
- Exhibit 81: Data Table on France - Year-over-year growth 2021-2026 (%)
- 7.12 Market opportunity by geography
- Exhibit 82: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.3 Impact of drivers and challenges
- Exhibit 83: Impact of drivers and challenges in 2021 and 2026
9 Vendor Landscape
- 9.2 Vendor landscape
- Exhibit 84: Overview on Criticality of inputs and Factors of differentiation
- 9.3 Landscape disruption
- Exhibit 85: Overview on factors of disruption
- 9.4 Industry risks
- Exhibit 86: Impact of key risks on business
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 87: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 88: Matrix on vendor position and classification
- 10.3 AIM ImmunoTech Inc.
- Exhibit 89: AIM ImmunoTech Inc. - Overview
- Exhibit 90: AIM ImmunoTech Inc. - Product / Service
- Exhibit 91: AIM ImmunoTech Inc. - Key offerings
- 10.4 Apotex Inc.
- Exhibit 92: Apotex Inc. - Overview
- Exhibit 93: Apotex Inc. - Product / Service
- Exhibit 94: Apotex Inc. - Key offerings
- 10.5 Bionpharma Inc.
- Exhibit 95: Bionpharma Inc. - Overview
- Exhibit 96: Bionpharma Inc. - Product / Service
- Exhibit 97: Bionpharma Inc. - Key offerings
- 10.6 Cadila Pharmaceuticals Ltd.
- Exhibit 98: Cadila Pharmaceuticals Ltd. - Overview
- Exhibit 99: Cadila Pharmaceuticals Ltd. - Business segments
- Exhibit 100: Cadila Pharmaceuticals Ltd. - Key offerings
- Exhibit 101: Cadila Pharmaceuticals Ltd. - Segment focus
- 10.7 Hikma Pharmaceuticals Plc
- Exhibit 102: Hikma Pharmaceuticals Plc - Overview
- Exhibit 103: Hikma Pharmaceuticals Plc - Business segments
- Exhibit 104: Hikma Pharmaceuticals Plc - Key offerings
- Exhibit 105: Hikma Pharmaceuticals Plc - Segment focus
- 10.8 Lupin Ltd.
- Exhibit 106: Lupin Ltd. - Overview
- Exhibit 107: Lupin Ltd. - Product / Service
- Exhibit 108: Lupin Ltd. - Key news
- Exhibit 109: Lupin Ltd. - Key offerings
- 10.9 Pfizer Inc.
- Exhibit 110: Pfizer Inc. - Overview
- Exhibit 111: Pfizer Inc. - Product / Service
- Exhibit 112: Pfizer Inc. - Key news
- Exhibit 113: Pfizer Inc. - Key offerings
- 10.10 Sun Pharmaceutical Industries Ltd.
- Exhibit 114: Sun Pharmaceutical Industries Ltd. - Overview
- Exhibit 115: Sun Pharmaceutical Industries Ltd. - Product / Service
- Exhibit 116: Sun Pharmaceutical Industries Ltd. - Key offerings
- 10.11 Teva Pharmaceutical Industries Ltd.
- Exhibit 117: Teva Pharmaceutical Industries Ltd. - Overview
- Exhibit 118: Teva Pharmaceutical Industries Ltd. - Business segments
- Exhibit 119: Teva Pharmaceutical Industries Ltd. - Key news
- Exhibit 120: Teva Pharmaceutical Industries Ltd. - Key offerings
- Exhibit 121: Teva Pharmaceutical Industries Ltd. - Segment focus
- 10.12 Viatris Inc.
- Exhibit 122: Viatris Inc. - Overview
- Exhibit 123: Viatris Inc. - Business segments
- Exhibit 124: Viatris Inc. - Key offerings
- Exhibit 125: Viatris Inc. - Segment focus
11 Appendix
- 11.2 Inclusions and exclusions checklist
- Exhibit 126: Inclusions checklist
- Exhibit 127: Exclusions checklist
- 11.3 Currency conversion rates for US$
- Exhibit 128: Currency conversion rates for US$
- 11.4 Research methodology
- Exhibit 129: Research methodology
- Exhibit 130: Validation techniques employed for market sizing
- Exhibit 131: Information sources
- 11.5 List of abbreviations
- Exhibit 132: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:[email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article